{"id":"https://openalex.org/W3097558747","doi":"https://doi.org/10.1182/blood-2020-140294","title":"Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study","display_name":"Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097558747","doi":"https://doi.org/10.1182/blood-2020-140294","mag":"3097558747"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-140294","doi":"https://doi.org/10.1182/blood-2020-140294","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-140294","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048566051","display_name":"Eva M. Gonz\u00e1lez-Barca","orcid":"https://orcid.org/0000-0002-1323-1508","observed_orcids":["https://orcid.org/0000-0002-1323-1508"]},"institutions":[{"id":"https://openalex.org/I4210087039","display_name":"Institut d'Investigaci\u00f3 Biom\u00e9dica de Bellvitge","ror":"https://ror.org/0008xqs48","country_code":"ES","type":"facility","lineage":["https://openalex.org/I157913058","https://openalex.org/I2802050225","https://openalex.org/I4210087039","https://openalex.org/I4210096656","https://openalex.org/I4210106543","https://openalex.org/I4210107147","https://openalex.org/I4210153292","https://openalex.org/I4387153040","https://openalex.org/I71999127"]},{"id":"https://openalex.org/I4210107147","display_name":"Institut Catal\u00e0 d'Oncologia","ror":"https://ror.org/01j1eb875","country_code":"ES","type":"government","lineage":["https://openalex.org/I4210107147"]},{"id":"https://openalex.org/I4210143012","display_name":"Duran i Reynals Hospital","ror":"https://ror.org/03qwghy04","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210143012"]},{"id":"https://openalex.org/I71999127","display_name":"Universitat de Barcelona","ror":"https://ror.org/021018s57","country_code":"ES","type":"education","lineage":["https://openalex.org/I71999127"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Eva Gonz\u00e1lez-Barca","raw_affiliation_strings":["Department of Hematology, Institut Catal\u00e1 d'Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Institut Catal\u00e1 d'Oncologia (ICO), Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain","institution_ids":["https://openalex.org/I4210087039","https://openalex.org/I4210107147","https://openalex.org/I4210143012","https://openalex.org/I71999127"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061317839","display_name":"Johannes Duell","orcid":"https://orcid.org/0000-0001-6935-7997","observed_orcids":["https://orcid.org/0000-0001-6935-7997"]},"institutions":[{"id":"https://openalex.org/I25974101","display_name":"University of W\u00fcrzburg","ror":"https://ror.org/00fbnyb24","country_code":"DE","type":"education","lineage":["https://openalex.org/I25974101"]},{"id":"https://openalex.org/I4210126310","display_name":"Universit\u00e4tsklinikum W\u00fcrzburg","ror":"https://ror.org/03pvr2g57","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210126310"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Johannes Duell","raw_affiliation_strings":["Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinik W\u00fcrzburg, W\u00fcrzburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinik W\u00fcrzburg, W\u00fcrzburg, Germany","institution_ids":["https://openalex.org/I25974101","https://openalex.org/I4210126310"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105456457","display_name":"Federica Cavallo","orcid":"https://orcid.org/0000-0003-2047-1099","observed_orcids":["https://orcid.org/0000-0003-2047-1099"]},"institutions":[{"id":"https://openalex.org/I55143463","display_name":"University of Turin","ror":"https://ror.org/048tbm396","country_code":"IT","type":"education","lineage":["https://openalex.org/I55143463"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Federica Cavallo","raw_affiliation_strings":["Department of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Turin, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular Biotechnologies and Health Sciences, Division of Hematology, University of Torino, Turin, Italy","institution_ids":["https://openalex.org/I55143463"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083191976","display_name":"Juan\u2010Manuel Sancho","orcid":"https://orcid.org/0000-0001-7168-6538","observed_orcids":["https://orcid.org/0000-0001-7168-6538"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I4210089592","display_name":"Josep Carreras Leukaemia Research Institute","ror":"https://ror.org/00btzwk36","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210089592","https://openalex.org/I4210144824","https://openalex.org/I4387153040"]},{"id":"https://openalex.org/I4210107147","display_name":"Institut Catal\u00e0 d'Oncologia","ror":"https://ror.org/01j1eb875","country_code":"ES","type":"government","lineage":["https://openalex.org/I4210107147"]},{"id":"https://openalex.org/I4210153460","display_name":"Hospital Universitari Germans Trias i Pujol","ror":"https://ror.org/04wxdxa47","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210153292","https://openalex.org/I4210153460"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Juan-Manuel Sancho","raw_affiliation_strings":["Departamento de Hematolog\u00eda, Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Aut\u00f2noma de Barcelona, Badalona, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento de Hematolog\u00eda, Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Aut\u00f2noma de Barcelona, Badalona, Barcelona, Spain","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I4210089592","https://openalex.org/I4210107147","https://openalex.org/I4210153460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101865823","display_name":"Zsolt Nagy","orcid":"https://orcid.org/0000-0001-9756-5427","observed_orcids":["https://orcid.org/0000-0001-9756-5427"]},"institutions":[{"id":"https://openalex.org/I101202996","display_name":"Semmelweis University","ror":"https://ror.org/01g9ty582","country_code":"HU","type":"education","lineage":["https://openalex.org/I101202996"]}],"countries":["HU"],"is_corresponding":false,"raw_author_name":"Zsolt Nagy","raw_affiliation_strings":["1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary","institution_ids":["https://openalex.org/I101202996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007117385","display_name":"Pau Abrisqueta","orcid":"https://orcid.org/0000-0001-9625-7422","observed_orcids":["https://orcid.org/0000-0001-9625-7422","https://orcid.org/0000-0003-3028-7500"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Pau Abrisqueta","raw_affiliation_strings":["Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067554119","display_name":"Carlos Panizo","orcid":"https://orcid.org/0000-0002-3945-585X","observed_orcids":["https://orcid.org/0000-0002-3945-585X"]},"institutions":[{"id":"https://openalex.org/I4210135003","display_name":"Clinica Universidad de Navarra","ror":"https://ror.org/03phm3r45","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210135003"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Carlos Panizo","raw_affiliation_strings":["Haematology Department, Cl\u00ednica Universitaria de Navarra, Navarra, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Haematology Department, Cl\u00ednica Universitaria de Navarra, Navarra, Spain","institution_ids":["https://openalex.org/I4210135003"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031158730","display_name":"Marinela Augustin","orcid":"https://orcid.org/0000-0003-0494-0422","observed_orcids":["https://orcid.org/0000-0003-0494-0422"]},"institutions":[{"id":"https://openalex.org/I4210116085","display_name":"Paracelsus Medizinische Privatuniversit\u00e4t","ror":"https://ror.org/022zhm372","country_code":"DE","type":"education","lineage":["https://openalex.org/I4210116085"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Marinela Augustin","raw_affiliation_strings":["Klinik f\u00fcr Innere Medizin 5, Universit\u00e4tsklinik der Paracelsus Medizinischen Privatuniversit\u00e4t, N\u00fcrnberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Klinik f\u00fcr Innere Medizin 5, Universit\u00e4tsklinik der Paracelsus Medizinischen Privatuniversit\u00e4t, N\u00fcrnberg, Germany","institution_ids":["https://openalex.org/I4210116085"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007901103","display_name":"Johannes Weirather","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Johannes Weirather","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007316044","display_name":"Sumeet Ambarkhane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144094060","display_name":"MorphoSys (Germany)","ror":"https://ror.org/00ew7rg06","country_code":"DE","type":"company","lineage":["https://openalex.org/I144094060"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Sumeet Ambarkhane","raw_affiliation_strings":["MorphoSys AG, Planegg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MorphoSys AG, Planegg, Germany","institution_ids":["https://openalex.org/I144094060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024389256","display_name":"Kami J. Maddocks","orcid":"https://orcid.org/0000-0001-8519-8404","observed_orcids":["https://orcid.org/0000-0001-8519-8404"]},"institutions":[{"id":"https://openalex.org/I2802841970","display_name":"The Ohio State University Wexner Medical Center","ror":"https://ror.org/00c01js51","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802841970"]},{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kami J. Maddocks","raw_affiliation_strings":["Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH","institution_ids":["https://openalex.org/I2802841970","https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014125875","display_name":"Nagesh Kalakonda","orcid":"https://orcid.org/0000-0002-5300-1360","observed_orcids":["https://orcid.org/0000-0002-5300-1360"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nagesh Kalakonda","raw_affiliation_strings":["Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, United Kingdom","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086354986","display_name":"Gilles A. Salles","orcid":"https://orcid.org/0000-0002-9541-8666","observed_orcids":["https://orcid.org/0000-0002-9541-8666"]},"institutions":[{"id":"https://openalex.org/I203339264","display_name":"Universit\u00e9 de Lyon","ror":"https://ror.org/01rk35k63","country_code":"FR","type":"education","lineage":["https://openalex.org/I203339264"]},{"id":"https://openalex.org/I4210100596","display_name":"Hospices Civils de Lyon","ror":"https://ror.org/01502ca60","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210100596"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Gilles Salles","raw_affiliation_strings":["H\u00e9matologie, Hospices Civils de Lyon and Universit\u00e9 de Lyon, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H\u00e9matologie, Hospices Civils de Lyon and Universit\u00e9 de Lyon, Lyon, France","institution_ids":["https://openalex.org/I203339264","https://openalex.org/I4210100596"]}]}],"institutions":[],"countries_distinct_count":7,"institutions_distinct_count":21,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4418,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.66402605,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"1","last_page":"2"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9922000169754028,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tafasitamab","display_name":"tafasitamab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9539999961853027},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9769999980926514},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9240000247955322},{"id":"https://openalex.org/keywords/double-hit-lymphoma","display_name":"double-hit lymphoma","score":0.8460000157356262},{"id":"https://openalex.org/keywords/triple-hit-lymphoma","display_name":"triple-hit lymphoma","score":1.0},{"id":"https://openalex.org/keywords/anti-cd19-monoclonal-antibody","display_name":"anti-CD19 monoclonal antibody","score":0.9409999847412109},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7549999952316284},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.847000002861023},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8159999847412109},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.37400001287460327}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.7664763331413269},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7100525498390198},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6555483341217041},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.6446647644042969},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5499111413955688},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.516152024269104},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5127852559089661},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5096368789672852},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.4634641706943512},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44144538044929504},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.4175356328487396},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.41533762216567993},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.27266544103622437},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.22601565718650818},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-140294","doi":"https://doi.org/10.1182/blood-2020-140294","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-140294","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2988395771","https://openalex.org/W4246296409","https://openalex.org/W3172444569","https://openalex.org/W3112732938","https://openalex.org/W4310163262","https://openalex.org/W3034162969","https://openalex.org/W4310127427","https://openalex.org/W3176363517","https://openalex.org/W3111145273","https://openalex.org/W4365514092"],"abstract_inverted_index":{"Introduction":[0],"Patients":[1,40,174,298,622],"with":[2,21,41,78,88,110,149,160,188,289,296,299,464,482,563,566,573,601,611,623,631,645,661,666],"diffuse":[3],"large":[4],"B-cell":[5,354],"lymphoma":[6,118],"(DLBCL)":[7],"that":[8,72],"is":[9,65,73,504],"refractory":[10,114,252,291,301,451,466,580,613,625],"to":[11,54,262,321,425,452,648],"primary":[12,230,290,300,465,579,612,624],"immunochemotherapy":[13],"are":[14,51],"well":[15],"recognized":[16],"as":[17,256,377],"a":[18,26,56,189,306,322,397,401,483,602,782],"high-risk":[19,111,361],"population":[20],"poor":[22],"prognosis,":[23],"and":[24,45,116,170,293,317,356,399,476,532,551,584,606,615,620,635],"have":[25],"typical":[27],"median":[28,132,307,323,496],"overall":[29],"survival":[30,524],"(OS)":[31],"of":[32,168,178,213,270,309,324,327,437,456,486,490,577,594,707],"6-13":[33],"months":[34,269,393,528,537,547,555],"[Farooq":[35],"U,":[36],"et":[37,101],"al.":[38,102],"2017].":[39],"'double-hit'":[42],"(MYCand":[43],"eitherBCL2orBCL6)":[44],"'triple-hit'":[46],"(MYC,":[47],"BCL2andBCL6)":[48],"genetic":[49],"aberrations":[50],"also":[52],"considered":[53],"be":[55,643],"high-risk/poor":[57],"prognosis":[58],"group":[59],"[Davies":[60],"A.":[61],"2019].":[62],"Tafasitamab":[63],"(MOR208)":[64],"an":[66,161,247,704],"Fc-enhanced,":[67],"humanized,":[68],"monoclonal":[69],"anti-CD19":[70],"antibody":[71],"under":[74],"investigation":[75],"in":[76,81,92,125,506,517,586,609,618,664],"combination":[77,593],"lenalidomide":[79],"(LEN)":[80],"autologous":[82],"stem":[83],"cell":[84],"transplant":[85],"(ASCT)-ineligible":[86],"patients":[87,109,143,220,288,295,350,372,381,388,407,416,439,463,512,562,610,665],"relapsed/refractory":[89],"(R/R)":[90],"DLBCL":[91,112,151,272,292,302,355],"the":[93,140,345,446,461,477,578,649],"Phase":[94],"II":[95],"L-MIND":[96,126,141,284,421],"study":[97,368],"(NCT02399085)":[98],"[Salles":[99],"G,":[100],"2020].":[103],"We":[104],"report":[105],"efficacy":[106],"data":[107,641],"for":[108,134,172],"(primary":[113],"disease":[115,227,253,626,634],"double/triple-hit":[117],"[DHL/THL])":[119],"who":[120,513],"received":[121,175,221,373,409],"tafasitamab":[122,179,222,595],"+":[123,240,596],"LEN":[124,204,597],"(data":[127],"cut-off:":[128],"Nov":[129],"30,":[130],"2019;":[131],"follow-up":[133],"OS,":[135],"31.8":[136],"months).":[137],"Methods":[138],"In":[139,460],"study,":[142],"enrolled":[144],"were":[145,274,318,450,627],"aged":[146],"\u226518":[147],"years":[148,311,630],"R/R":[150],"(1-3":[152],"prior":[153,412],"systemic":[154],"therapies,":[155],"including":[156],"\u22651":[157],"CD20-targeting":[158],"regimen),":[159],"Eastern":[162],"Cooperative":[163],"Oncology":[164],"Group":[165],"performance":[166],"status":[167,366],"0-2":[169],"ineligible":[171],"ASCT.":[173],"28-day":[176],"cycles":[177],"(12":[180],"mg/kg":[181],"intravenously),":[182],"once":[183],"weekly":[184],"during":[185,201,265],"Cycles":[186,202,214],"1-3":[187],"loading":[190],"dose":[191],"on":[192,210,703],"Cycle":[193,217],"1":[194,411,508],"Day":[195],"4,":[196],"then":[197],"every":[198,223],"2":[199,224,325],"weeks":[200,225],"4-12.":[203],"(25":[205],"mg":[206],"orally)":[207],"was":[208,232,254,430,469,480,526,538,545,556],"administered":[209],"Days":[211],"1-21":[212],"1-12.":[215],"After":[216],"12,":[218],"progression-free":[219,523],"until":[226],"progression.":[228],"The":[229,283,592],"endpoint":[231],"objective":[233],"response":[234,238,242,258,487,502],"rate":[235,479,489,534,608],"(ORR)":[236],"(partial":[237],"[PR]":[239],"complete":[241],"[CR]),":[243],"assessed":[244],"centrally":[245],"by":[246],"independent":[248],"review":[249],"committee.":[250],"Primary":[251],"defined":[255],"no":[257,384],"(CR":[259],"or":[260,263,266,360,375,709,739,746,750,754,759,764,769,774,779,787],"PR)":[261,402],"progression":[264,426],"within":[267,391,442],"6":[268,392],"frontline":[271,404],"therapy.MYC,BCL2andBCL6aberrations":[273],"determined":[275],"via":[276],"fluorescencein":[277],"situhybridization":[278],"using":[279],"tumor":[280],"biopsy.":[281],"Results":[282],"cohort":[285],"included":[286],"15":[287,371,438,447,462],"two":[294,380,436],"DHL/THL.":[297],"at":[303,367,535,553],"baseline":[304],"had":[305,335,351,389,395,408,417,440],"age":[308],"73":[310],"(range":[312,329,433],"48-82;":[313],"n=9":[314],"\u226570":[315,629],"years)":[316],"previously":[319,382],"exposed":[320],"lines":[326,419],"treatment":[328],"1-4).":[330],"Of":[331,445],"these":[332,640,654],"patients,":[333,448],"ten":[334,339],"stage":[336,632],"III/IV":[337,633],"disease,":[338,467],"showed":[340,598],"lactate":[341],"dehydrogenase":[342],"greater":[343],"than":[344],"upper":[346],"normal":[347],"limit,":[348],"12":[349],"germinal":[352],"center":[353],"eight":[357],"exhibited":[358],"intermediate-high":[359],"International":[362],"Prognostic":[363],"Index":[364],"(IPI)":[365],"baseline.":[369],"All":[370],"R-CHOP":[374],"equivalent":[376],"first-line":[378,428],"therapy;":[379],"achieved":[383,396,514,568,582],"response,":[385],"whereas":[386,414],"13":[387,449],"relapsed":[390],"(ten":[394],"CR":[398,478,515,583,607],"3":[400],"after":[403,427,519,588],"therapy.":[405],"Six":[406],"only":[410],"therapy,":[413],"nine":[415],"\u22652":[418],"before":[420,458],"enrollment.":[422],"Median":[423,522,543],"time":[424],"therapy":[429,457],"162":[431],"days":[432],"28-182":[434],"days);":[435],"progressed":[441],"90":[443],"days.":[444],"their":[453],"last":[454],"line":[455],"L-MIND.":[459],"ORR":[468,605],"53.3%":[470],"(95%":[471,492,529,540,548,558],"confidence":[472],"interval":[473],"[CI]:":[474],"26.6-78.7)":[475],"33.3%,":[481],"30-month":[484],"duration":[485,503],"(DOR)":[488],"50%":[491],"CI:":[493,530,541,549,559],"15.2-77.5)":[494],"-":[495],"DOR":[497],"not":[498],"reached":[499],"(NR).":[500],"Individual":[501],"shown":[505],"Figure":[507],"(swimmer":[509],"plot):":[510],"four":[511],"remain":[516],"remission":[518,587],">30":[520,589],"months.":[521,590],"(PFS)":[525],"5.3":[527],"0.9-NR)":[531],"PFS":[533],"30":[536],"33.9%":[539],"11.0-58.8).":[542],"OS":[544,552],"13.8":[546],"1.3-NR)":[550],"36":[554],"38.1%":[557],"14.6-61.6).":[560],"Regarding":[561],"DHL/THL:":[564],"one":[565],"DHL":[567,619],"PR":[569],"only;":[570],"another":[571],"patient":[572,651],"THL":[574],"(also":[575],"part":[576],"subgroup)":[581],"remains":[585],"Conclusions":[591],"encouraging":[599],"activity,":[600],"clinically":[603,655],"meaningful":[604],"DLBCL,":[614],"positive":[616],"responses":[617],"THL.":[621],"frequently":[628],"poor-risk":[636],"IPI":[637],"scores.":[638],"Although":[639],"should":[642],"interpreted":[644],"caution":[646],"due":[647],"small":[650],"subgroup":[652],"sizes,":[653],"relevant":[656],"results":[657],"warrant":[658],"further":[659],"research":[660],"this":[662],"immunotherapy":[663],"difficult-to-treat":[667],"DLBCL.":[668],"Disclosures":[669],"Gonz\u00e1lez-Barca:":[670],"MorphoSys:Other;Janssen:Consultancy,":[671],"Honoraria;Sandoz:Consultancy;Gilead:Consultancy;Roche:Honoraria;Takeda:Honoraria;Abbvie:Honoraria;Celgene:Consultancy;Kiowa:Consultancy;Celtrion:Consultancy.Duell:Morphosys:Research":[672],"Funding.Sancho:Bristol-Myers":[673],"Squibb:Honoraria;Celgene:Consultancy,":[674],"Honoraria;Gilead:Consultancy,":[675],"Honoraria;Janssen:Consultancy,":[676],"Honoraria;Kern-Pharma:Consultancy,":[677],"Honoraria;Novartis:Consultancy,":[678],"Honoraria;Roche:Consultancy,":[679],"Honoraria;Takeda:Honoraria;Celltrion:Consultancy;Sandoz:Consultancy.Nagy:MorphoSys":[680],"AG:Patents":[681],"&":[682],"Royalties.Abrisqueta:Celgene:Consultancy,":[683],"Honoraria;AbbVie:Consultancy,":[684],"Honoraria,":[685,688,691,743],"Speakers":[686,689,692],"Bureau;Roche:Consultancy,":[687],"Bureau;Janssen:Consultancy,":[690],"Bureau.Panizo:Cl\u00ednica":[693],"Universidad":[694],"de":[695],"Navarra:Current":[696],"Employment;Bristol-Myers":[697],"Squibb,":[698],"Kyowa":[699],"Kirin:Speakers":[700],"Bureau;Janssen,":[701],"Roche:Membership":[702],"entity's":[705],"Board":[706],"Directors":[708],"advisory":[710,740,747,751,755,760,765,770,775,780,788],"committees.Augustin:Morphosys:Research":[711],"Funding;AstraZeneca:Consultancy,":[712],"Research":[713,715,717,719,721,734],"Funding;Roche:Consultancy;Novartis:Consultancy,":[714],"Funding;Merck:Consultancy;IPSEN:Consultancy,":[716],"Funding;Pfizer:Consultancy,":[718],"Funding;BMS:Consultancy,":[720],"Funding.Weirather:MorphoSys":[722],"AG:Current":[723,725],"Employment.Ambarkhane:MorphoSys":[724],"Employment.Maddocks:Seattle":[726],"Genetics:Consultancy,":[727],"Honoraria;Celgene:Consultancy,":[728],"Honoraria;Pharmacyclics:Consultancy,":[729],"Honoraria;Morphosys:Consultancy,":[730],"Honoraria;ADC":[731],"Therapeutics,":[732],"AstraZeneca:Consultancy;BMS:Consultancy,":[733],"Funding;Karyopharm:Consultancy.Kalakonda:Celgene:Research":[735],"Funding.Salles:BMS/Celgene:Honoraria,":[736],"Other:":[737,744,757,762,767,772,777,785],"consultancy":[738,745,749,753,758,763,768,773,778,786],"role;Takeda:Honoraria;Karyopharm:Honoraria;Genmab:Honoraria,":[741],"Other;Debiopharm:Consultancy,":[742],"role;Autolos:Other:":[748],"role;Abbvie:Other:":[752],"role;Roche:Honoraria,":[756],"role;Novartis:Honoraria,":[761],"role;MorphoSys:Honoraria,":[766],"role;Janssen:Honoraria,":[771],"role;Epizyme:Honoraria,":[776],"role;Kite,":[781],"Gilead":[783],"Company:Honoraria,":[784],"role":[789],".":[790]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2020-11-09T00:00:00"}